Search
Methylchloroisothiazolinone
go.drugbank.com/drugs/DB14197ApprovedThe American Contact Dermatitis Society named Methylchloroisothiazolinone the Contact Allergen of the Year for 2013. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.
Categories: Compounds used in a research, industrial, or household settingBenzhydrocodone
go.drugbank.com/drugs/DB15465Approved[A182177] Benzhydrocodone is indicated for use in the short-term management of pain. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalCeritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of … Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells
Rifapentine
go.drugbank.com/drugs/DB01201ApprovedInvestigationalSpecifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisAlunacedase alfa
go.drugbank.com/drugs/DB15736InvestigationalAlunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Categories: Experimental Unapproved Treatments for COVID-19Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Nebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigational[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].
Categories: Antihypertensive Agents Indicated for HypertensionBatroxobin
go.drugbank.com/drugs/DB09005InvestigationalBatroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. … Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.
N4-Hydroxycytidine
go.drugbank.com/drugs/DB15660Experimental[A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation … [A193014] The prodrug of N4-hydroxycytidine, [EIDD-2801], is also being investigated for its broad spectrum activity against the coronavirus family of viruses.[A193014]
Categories: Experimental Unapproved Treatments for COVID-19